Immuneering Stock
Immuneering Corporation
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Benjamin J. Zeskind
- Employees
- 57
- Market cap
- $232 M
- IPO
- 30/07/2021
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including…
Immuneering stock: price history
1D
-1.4%
1W
-8.9%
1M
-19.3%
6M
-35.4%
YTD
-45.4%
1Y
-35.2%
2Y
+61.7%
5Y
-85.6%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~5% weaker price swings than usual
Ask the agents about Immuneering
Analyst assessment of Immuneering
PRICE TARGET LOW
US$14.00
CONSENSUS
US$15.50
MEDIAN
US$15.50
PRICE TARGET HIGH
US$17.00
0
STRONG BUY
7
BUY
4
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 20/07/2026
Immuneering stock metrics
P/E
-3.45
P/B
1.22
EV/EBITDA
-3.15
RETURN ON EQUITY
-9.1%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
76.1%
FLOAT SHARES
49,210,138
AVG. DAILY VOLUME (30D)
761,848
Insider transactions (SEC)
Zeskind Benjamin J.
Hall Brett Matthew
Institutional holders
Comparable stocks
Frequently asked questions about Immuneering stock
What does Immuneering do?
Immuneering Corporation is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Benjamin J. Zeskind, the company employs around 57 people.
The IPO was on 30/07/2021; the stock trades on NASDAQ under the ticker IMRX.
What do analysts say about Immuneering stock?
11 analysts rate the stock, the consensus is Buy (as of 20/07/2026).
The average price target is US$15.50, ranging from US$14.00 to US$17.00, with a median of US$15.50.
This is an external assessment, not a statement by Market Jury.
When does Immuneering report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -5% stronger than usual.
Does Immuneering pay a dividend?
No, Immuneering currently does not pay a dividend.
Which stocks are comparable to Immuneering?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Immuneering stock analyzed?
Clicking "Analyze stock" lets five strategies assess Immuneering against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.